08/28/2025
Adding this to the top of the post to make sure it is seen:
"Dr. David Dycus
8h
·
This is an interesting abstract that was sent to me. Things are beginning to look eerily familiar to what was seen on the human side and as such the product was pulled. We are seeing musculoskeletal AE such as joint destruction (RPOA or RPOA like), and now an abstract sponsored by the company showing no real benefit (or superiority) in using Librela compared to using an NSAID (or least they showed it is "good enough"). However, we know a lot more about AE and chronic use of NSAIDs compared to long term use of Librela, which we know nothing about.
I wonder if this will get buried because of the less than stellar findings or if the ethical aspect is done and it is published to go through the rigors of peer review...
Guess time will tell
This is an interesting abstract that was sent to me. Things are beginning to look eerily familiar to what was seen on the human side and as such the product was pulled. We are seeing musculoskeletal AE such as joint destruction (RPOA or RPOA like), and now an abstract sponsored by the company showing no superiority in using Librela compared to using an NSAID. However, we know a lot more about AE and chronic use of NSAIDs compared to long term use of Librela, which we know nothing about.
Guess time will tell